Европска Унија - Словеначки - EMA (European Medicines Agency)

actavis group ptc ehf - levetiracetam - epilepsija - antiepileptics, - levetiracetam actavis je označen kot monoterapije pri zdravljenju zasegov delno nastopom z ali brez sekundarnega posploševanje pri bolnikih od 16 let z novo diagnosticirano epilepsijo. levetiracetam actavis je označen kot adjunctive terapija:pri zdravljenju delno-nastop napadi z ali brez sekundarne posplošitev v odrasle, otroke in dojenčke od enega meseca starosti z epilepsijo;pri zdravljenju myoclonic zasegov v odrasle in mladostnike od 12. leta starosti z mladoletnimi myoclonic epilepsija;v zdravljenju primarne splošni tonik-clonic zasegov v odrasle in mladostnike od 12. leta starosti z idiopatsko splošnih epilepsijo.

Европска Унија - Словеначки - EMA (European Medicines Agency)

ratiopharm gmbh - levetiracetam - epilepsija - antiepileptics, - levetiracetam izkazala družba ratiopharm je označen kot monoterapije pri zdravljenju zasegov delno nastopa z ali brez sekundarnega posploševanje pri bolnikih od 16 let z novo diagnosticirano epilepsijo. levetiracetam ratiopharm je označen kot adjunctive terapija:pri zdravljenju delno nastop napadi z ali brez sekundarne posplošitev v odrasle, otroke in dojenčke od 1 meseca starosti z epilepsijo;pri zdravljenju myoclonic zasegov v odrasle in mladostnike od 12. leta starosti z mladoletnimi myoclonic epilepsija;v zdravljenju primarne splošni tonik-clonic zasegov v odrasle in mladostnike od 12. leta starosti z idiopatsko splošnih epilepsijo.

Европска Унија - Словеначки - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - levetiracetam - epilepsija - drugi antiepileptics - zdravilo levetiracetam sun je indicirano kot monoterapija pri zdravljenju napadov s parcialnim nastopom s sekundarno generalizacijo ali brez nje pri bolnikih od 16. leta starosti z novo diagnosticirano epilepsijo. levetiracetam sonce je označen kot adjunctive terapija:pri zdravljenju delno-nastop napadi z ali brez sekundarne posplošitev v odrasle in otroke od štirih let z epilepsijo;pri zdravljenju myoclonic zasegov v odrasle in mladostnike od 12. leta starosti z mladoletnimi myoclonic epilepsija;v zdravljenju primarne splošni tonik-clonic zasegov v odrasle in mladostnike od 12. leta starosti z idiopatsko splošnih epilepsijo. levetiracetam sonce koncentrat je alternativa za bolnike, ko ustni uprava je začasno ni izvedljivo,.

Европска Унија - Словеначки - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibacterials za sistemsko uporabo, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.

Европска Унија - Словеначки - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - ceftaroline fosamil - community-acquired infections; skin diseases, infectious; pneumonia - antibacterials za sistemsko uporabo, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.

Европска Унија - Словеначки - EMA (European Medicines Agency)

juta pharma gmbh - pegfilgrastim - nevtropenija - immunostimulants, - skrajšanje trajanja nevtropenija in pojavnost vročinskih nevtropenija pri odraslih bolnikih, zdravljenih s citotoksično kemoterapijo za malignosti (razen kronično mieloično levkemijo in mielodisplastični sindrom).

Европска Унија - Словеначки - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.